GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » EV-to-Revenue

Paradigm Biopharmaceuticals (ASX:PAR) EV-to-Revenue : 1,543.83 (As of May. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Paradigm Biopharmaceuticals's enterprise value is A$64.84 Mil. Paradigm Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.04 Mil. Therefore, Paradigm Biopharmaceuticals's EV-to-Revenue for today is 1,543.83.

The historical rank and industry rank for Paradigm Biopharmaceuticals's EV-to-Revenue or its related term are showing as below:

ASX:PAR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: 1543.83

ASX:PAR's EV-to-Revenue is ranked worse than
96.34% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs ASX:PAR: 1543.83

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), Paradigm Biopharmaceuticals's stock price is A$0.28. Paradigm Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Paradigm Biopharmaceuticals's PS Ratio for today is .


Paradigm Biopharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Paradigm Biopharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals EV-to-Revenue Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial - - 19,643.82 2,347.84 4,743.56

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,347.84 - 4,743.56 -

Competitive Comparison of Paradigm Biopharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's EV-to-Revenue falls into.



Paradigm Biopharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Paradigm Biopharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=64.841/0.042
=1,543.83

Paradigm Biopharmaceuticals's current Enterprise Value is A$64.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals  (ASX:PAR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Paradigm Biopharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.28/0
=

Paradigm Biopharmaceuticals's share price for today is A$0.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).